The global healthcare and biopharmaceutical industry is witnessing increasing attention toward therapies associated with fibrinolysis regulation and cardiovascular disease management. Plasminogen activator inhibitors have emerged as critical components in therapeutic research due to their involvement in blood clot regulation, tissue remodeling, and inflammatory pathways. Growing clinical...